Van ECK Associates Corp Purchases 2,171 Shares of IQVIA Holdings Inc. $IQV

Van ECK Associates Corp increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 117,970 shares of the medical research company’s stock after buying an additional 2,171 shares during the period. Van ECK Associates Corp’s holdings in IQVIA were worth $22,794,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC grew its holdings in IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in IQVIA in the 2nd quarter worth approximately $514,000. First Trust Advisors LP lifted its holdings in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after acquiring an additional 1,155 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on IQV shares. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. BMO Capital Markets boosted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Royal Bank Of Canada upped their price objective on shares of IQVIA from $221.00 to $247.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. TD Cowen lifted their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Price Performance

Shares of IQVIA stock opened at $260.48 on Monday. The firm has a market cap of $42.88 billion, a P/E ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The firm’s 50-day simple moving average is $222.14 and its 200-day simple moving average is $189.59. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $265.25. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, insider W Richard Staub sold 5,500 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.